The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options

Disanto, G. and Benkert, P. and Lorscheider, J. and Mueller, S. and Vehoff, J. and Zecca, C. and Ramseier, S. and Achtnichts, L. and Findling, O. and Nedeltchev, K. and Radue, E. W. and Sprenger, T. and Stippich, C. and Derfuss, T. and Louvion, J. F. and Kamm, C. P. and Mattle, H. P. and Lotter, C. and Du Pasquier, R. and Schluep, M. and Pot, C. and Lalive, P. H. and Yaldizli, O. and Gobbi, C. and Kappos, L. and Kuhle, J. and Smsc Scientific Board, . (2016) The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS One, 11 (3). e0152347.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/61671/

Downloads: Statistics Overview


The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic, clinical, MRI data and body fluids that can be used to develop prognostic indicators and biomarkers of disease evolution and therapeutic response. The Swiss MS Cohort (SMSC) is a prospective observational study performed across seven Swiss MS centers including patients with MS, clinically isolated syndrome (CIS), radiologically isolated syndrome or neuromyelitis optica. Neurological and radiological assessments and biological samples are collected every 6-12 months. We recruited 872 patients (clinically isolated syndrome [CIS] 5.5%, relapsing-remitting MS [RRMS] 85.8%, primary progressive MS [PPMS] 3.5%, secondary progressive MS [SPMS] 5.2%) between June 2012 and July 2015. We performed 2,286 visits (median follow-up 398 days) and collected 2,274 serum, plasma and blood samples, 152 cerebrospinal fluid samples and 1,276 brain MRI scans. 158 relapses occurred and expanded disability status scale (EDSS) scores increased in PPMS, SPMS and RRMS patients experiencing relapses. Most RRMS patients were treated with fingolimod (33.4%), natalizumab (24.5%) or injectable DMDs (13.6%). The SMSC will provide relevant information regarding DMDs efficacy and safety and will serve as a comprehensive infrastructure available for nested research projects.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Clinical Neuroimmunology (Derfuss/Lindberg)
UniBasel Contributors:Derfuss, Tobias Johannes
Item Type:Article, refereed
Article Subtype:Research Article
ISSN:1932-6203 (Electronic) 1932-6203 (Linking)
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:07 May 2019 16:06
Deposited On:07 May 2019 16:06

Repository Staff Only: item control page